Voya Investment Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 762,770 shares of the medical research company's stock after selling 43,058 shares during the quarter. Voya Investment Management LLC owned 0.20% of Thermo Fisher Scientific worth $396,687,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the stock. Dauntless Investment Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $240,000. Integrated Wealth Concepts LLC grew its stake in Thermo Fisher Scientific by 11.5% in the 4th quarter. Integrated Wealth Concepts LLC now owns 6,329 shares of the medical research company's stock worth $3,292,000 after buying an additional 652 shares in the last quarter. Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in shares of Thermo Fisher Scientific by 7.0% in the 4th quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 22,856 shares of the medical research company's stock worth $11,945,000 after buying an additional 1,500 shares during the last quarter. Burling Wealth Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $508,000. Finally, J. Stern & Co. LLP increased its stake in Thermo Fisher Scientific by 5.9% in the fourth quarter. J. Stern & Co. LLP now owns 57,538 shares of the medical research company's stock valued at $29,933,000 after acquiring an additional 3,198 shares during the last quarter. Institutional investors own 89.23% of the company's stock.
Insider Buying and Selling at Thermo Fisher Scientific
In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 in the last three months. 0.33% of the stock is currently owned by corporate insiders.
Thermo Fisher Scientific Stock Performance
TMO traded down $2.69 during trading on Monday, hitting $421.55. The company's stock had a trading volume of 2,527,205 shares, compared to its average volume of 1,746,667. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88. The business's 50 day simple moving average is $487.28 and its 200-day simple moving average is $526.70. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The firm has a market cap of $159.13 billion, a PE ratio of 25.50, a P/E/G ratio of 2.99 and a beta of 0.86.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business's quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.11 earnings per share. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a yield of 0.41%. Thermo Fisher Scientific's payout ratio is currently 10.09%.
Analyst Ratings Changes
A number of brokerages recently weighed in on TMO. Sanford C. Bernstein raised Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a report on Friday, January 10th. Raymond James reissued an "outperform" rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company dropped their target price on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $616.95.
Get Our Latest Stock Report on Thermo Fisher Scientific
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
